Who are Pentoxifylline sustained-release tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eucrisa, Eucrisa, Stendra, Daliresp, Pletal, Viagra.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pentoxifylline-sustained-release-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Pentoxifylline sustained-release tablets — Competitive Intelligence Brief

Pentoxifylline sustained-release tablets (Pentoxifylline sustained-release tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Methylxanthine derivative; phosphodiesterase inhibitor. Area: Cardiovascular.

marketed Methylxanthine derivative; phosphodiesterase inhibitor Phosphodiesterase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Pentoxifylline sustained-release tablets (Pentoxifylline sustained-release tablets) — Beijing Tiantan Hospital. Pentoxifylline improves blood flow and reduces inflammation by inhibiting phosphodiesterase enzymes and modulating cytokine production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pentoxifylline sustained-release tablets TARGET	Pentoxifylline sustained-release tablets	Beijing Tiantan Hospital	marketed	Methylxanthine derivative; phosphodiesterase inhibitor	Phosphodiesterase
Eucrisa	Crisaborole	Anacor Pharms Inc	marketed	PDE-4 inhibitor	Phosphodiesterase 4 (PDE-4)	2016-01-01
Eucrisa	CRISABOROLE	Anacor Pharms Inc	marketed	Phosphodiesterase 4 Inhibitor [EPC]	Phosphodiesterase 4	2016-01-01
Stendra	AVANAFIL	Vivus Llc	marketed	Phosphodiesterase 5 Inhibitor [EPC]	cGMP-specific 3',5'-cyclic phosphodiesterase	2012-01-01
Daliresp	ROFLUMILAST	Arcutis	marketed	Phosphodiesterase 4 Inhibitor [EPC]	cAMP-specific 3',5'-cyclic phosphodiesterase 4D	2011-01-01
Pletal	CILOSTAZOL	Otsuka	marketed	Phosphodiesterase 3 Inhibitor [EPC]	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	1999-01-01
Viagra	sildenafil	Pfizer Inc.	marketed	PDE5 inhibitor	Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, Multidrug resistance-associated protein 5	1998-03-27

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Methylxanthine derivative; phosphodiesterase inhibitor class)

Beijing Tiantan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pentoxifylline sustained-release tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/pentoxifylline-sustained-release-tablets. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab